Business Context and Reporting Period
Company: Illumina, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 28, 2008
Business Overview: Illumina is a leading developer of integrated systems for the large-scale analysis of genetic variation and biological function. The company serves sequencing, genotyping, and gene expression markets through its Genome Analyzer, BeadArray, and VeraCode platforms. In 2008, the company reorganized into Life Sciences and Diagnostics segments, though results were reported as a single segment due to limited Diagnostics activity.
Key Financial Metrics
| Metric | 2008 (in millions) | 2007 (in millions) |
|---|---|---|
| Total Revenue | $573.2 | $366.8 |
| Net Income (Loss) | $50.5 | $(278.4) |
| Operating Income (Loss) | $80.5 | $(301.2) |
| Diluted EPS | $0.38 | $(2.57) |
| Cash, Cash Equivalents & Investments | $696.0 | $386.1 |
| Working Capital | $355.4 | $397.0 |
| Long-term Debt (Current Portion) | $400.0 | $0.0 |
Note: The $400 million convertible senior notes were reclassified as current liabilities in 2008 because conversion conditions were met during the third quarter.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 56% to $573.2 million, driven by a 63% increase in product revenue. This was primarily due to strong demand for Infinium BeadChips and sequencing systems (Genome Analyzer II).
- Profitability Turnaround: The company returned to profitability with $50.5 million in net income, compared to a $278.4 million net loss in 2007. The 2007 loss was heavily impacted by a $303.4 million in-process research and development (IPR&D) charge from the Solexa acquisition and a $54.0 million litigation settlement charge.
- Acquisition Activity: Illumina acquired Avantome, Inc. in August 2008 for $25.8 million in cash plus up to $35.0 million in contingent consideration. This resulted in a $24.7 million IPR&D charge in 2008.
- Capital Structure: The company raised $342.6 million in net proceeds from a secondary public offering of common stock in August 2008. Additionally, it repurchased 3.1 million shares for $70.8 million under a new $120 million program.
- International Sales: Shipments to customers outside the U.S. grew to 51% of total revenue in 2008, up from 43% in 2007.
Guidance, Outlook, and Risks
- Outlook: Management expects to enter the molecular diagnostics market in 2009, targeting a market estimated at nearly $3 billion. The company plans to submit its VeraCode platform for FDA review in 2009. R&D expenses are expected to increase in 2009 to support product development.
- Liquidity Risk (Auction Rate Securities): As of December 28, 2008, the company held $55.9 million in auction rate securities that had become illiquid due to market failures. While a settlement with UBS allows the company to sell these at par between 2010 and 2012, there is a risk that UBS may not fulfill its obligation. The company recorded an $8.7 million unrealized loss on these assets.
- Convertible Notes: The $400 million convertible notes became convertible into cash and/or stock during 2008. While the conversion trigger was not met in Q4 2008, future stock price fluctuations could trigger conversion, impacting working capital.
- Competition and Obsolescence: The company faces intense competition from firms like Affymetrix and Life Technologies. Rapid technological changes could render current products obsolete.
- Legal Proceedings: A patent dispute with Applied Biosystems regarding Solexa patents concluded in January 2009 with a jury ruling in favor of Illumina regarding ownership, though appeals are possible.
Key Facts for Investor Verification
- Revenue Mix: Verify the sustainability of the 56% revenue growth, specifically the reliance on new product introductions (Infinium HD, Genome Analyzer II) versus volume increases.
- Auction Rate Securities: Confirm the status of the $55.9 million illiquid investment portfolio and the enforceability of the UBS settlement agreement.
- Convertible Debt: Monitor the stock price relative to the conversion price ($21.83) to assess the risk of cash outflow from note conversions in future quarters.
- One-Time Charges: Distinguish between recurring operating performance and non-recurring items (IPR&D charges, litigation settlements) when analyzing year-over-year profitability trends.
- International Exposure: Assess the impact of foreign currency fluctuations on the 51% of revenue generated outside the U.S., noting the company's shift to a U.S. dollar functional currency for subsidiaries.